Aes-103 5-hydroxymethyl-2-furfural: Phase II start

This month, AesRx will begin a double-blind, placebo-controlled Phase II trial to evaluate Aes-103 for 28 days in up to about 100 SCD patients. The first cohort of the trial will evaluate 100 mg Aes-103 4 times daily in about 20 patients. AesRx said the trial is part of a deal between it and NIH's National Center for Advancing Translational Sciences (NCATS) through NCATS's Therapeutics for Rare and Neglected Diseases (TRND) program. ...